Genedata Aids Merus in Development of Precision Immunotherapies
Genedata provides its scalable data management and analysis platform, Genedata Profiler, as managed SaaS for translational and clinical research
June 25, 2020
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that it has entered into a multi-year contract with Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and clinical research strategy to discover and develop ground-breaking drugs. The agreement includes a software license to the Genedata Profiler® platform as well as a variety of service arrangements, including consulting services and Managed IT Services, a recently added offering to the Genedata Service Portfolio.
Under the terms of the agreement, Genedata is committed to maintaining full operational responsibility for the software. In addition, Genedata has agreed to provide consulting services for workflow setup, data integration, and user training to get Merus productive with Genedata Profiler quickly and efficiently.
“Our unique technology uses large-scale functional screening in molecular and cell-based assays to identify unique oncology therapeutic multispecific antibody candidates from among thousands tested against an array of targets,” said John de Kruif, Ph.D., Chief Technology Officer of Merus. “We have long understood and valued the importance of being able to collect and analyze complex data sets in order to optimize the discovery of new combinations and modes of action. As we expect our clinical and pre-clinical programs and pipeline to continue to grow, we look forward to utilizing Genedata Profiler and Genedata Managed IT Services to assist us in our mission to develop safe, targeted, effective therapeutics for cancer patients.”
Genedata Profiler permits Merus’ scientists to leverage all the data and knowledge from past, current and future preclinical experiments and clinical trials, facilitating efficient translational and reverse translational research. It fosters secure collaboration between internal and external research groups and empowers users to make data-informed decisions with powerful, well-engineered analytical tools. Genedata Profiler depicts and tracks the whole data life cycle in a secure way with easy-to-use, fully configurable workflows, straight out of the box.
“We are excited to add Merus, a leading innovator in the oncology and multispecific antibody space, to our rapidly growing list of biopharmaceutical companies that have recognized the value that Genedata Profiler can bring to their translational and clinical research programs”, said Othmar Pfannes, Ph.D., CEO of Genedata. “With the expansion of our services portfolio to include Managed IT Services, we also demonstrate our commitment to medium sized biopharmaceutical companies who are looking for an all-in-one service provider. We remain committed to supporting our customers in making their R&D processes more efficient and scalable.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
We look forward to utilizing Genedata Profiler and Genedata Managed IT Services to assist us in our mission to develop safe, targeted, effective therapeutics for cancer patients
John de Kruif, Ph.D.
Chief Technology Officer